Pacira (PCRX) BioSciences announced that Laura Brege has been appointed Chair of the Board. Former Chair Paul J. Hastings and Andreas Wicki, PhD. have retired from the Board. These changes align with Pacira’s ongoing commitment to Board refreshment. With these changes, the Board is composed of nine directors, eight of whom are independent and five of whom have joined since October 2023.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- Pacira upgraded to Hold from Sell at Truist
- Pacira Pharmaceuticals Announces Leadership Changes and Plan Amendment
- Pacira appoints Teehan as CCO, Corbett as CBO
- Shareholders that lost money on Pacira BioSciences, Inc.(PCRX) should contact Levi & Korsinsky LLP about pending Class Action – PCRX
- Pacira price target raised to $30 from $22 at Needham